Finance

Lists
Why is LUNG down 2.68%?
Dive Deeper
LUNG:NASDAQ
Pulmonx Corp
$2.90
-2.68%
(-0.080) 1D
Nov 12, 9:42:44 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LUNG...
Open
$2.95
High
$3.00
Low
$2.88
Mkt. cap
126.30M
Avg. vol.
925.72K
Volume
16.97K
52-wk high
$3.25
52-wk low
$1.13
EPS
-$1.01
Beta
0.19
Shares outstanding
43.55M
No. of employees
296
Open
$2.95
High
$3.00
Low
$2.88
Mkt. cap
126.30M
Avg. vol.
925.72K
Volume
16.97K
52-wk high
$3.25
52-wk low
$1.13
EPS
-$1.01
Beta
0.19
Shares outstanding
43.55M
No. of employees
296
News stories
From web sources and news partners
About Pulmonx Corp
CEO-
Employees296
Founded1995
HeadquartersRedwood City, California, United States
SectorHealth Care
IndustryMedical device
Websitepulmonx.com
Analyst ratings
Based on 4 analysts giving stock ratings to LUNG in the past 3 months
Buy
Buy
2
Hold
2
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for LUNG in the last 3 months.
Highest
Current $2.90
$5.00 (+72.41%)
Average
$3.63 (+25.17%)
Lowest
$2.50 (-13.79%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Young CFA
Canaccord Genuity
Buy
Reiterated
$5.00
+72.4%
10/28/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
$3.00
+3.4%
10/28/2026
Jason Bednar
Piper Sandler
Hold
Reiterated
$2.50
-13.8%
10/28/2026
Rick Wise
Stifel Nicolaus
Buy
Reiterated
$4.00
+37.9%
10/28/2026
Frank Takkinen
Lake Street
Buy
Reiterated
$4.00
+37.9%
07/30/2026
William Plovanic
Canaccord Genuity
Buy
Reiterated
$5.00
+72.4%
04/30/2026
Last report
Oct 27, 2026
Fiscal period
Q3 2026
-$0.19 / -$0.26
+25.78%beat
Revenue / Est. (USD)
22.84M / 21.94M
+4.06%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
22.60M
20.59M
22.76M
22.84M
Cost of goods sold
5.06M
4.54M
5.01M
5.44M
Cost of revenue
5.06M
4.54M
5.01M
5.44M
Research and development expenses
4.58M
4.90M
5.03M
4.86M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
22.86M
24.10M
21.76M
20.02M
Operating expense
27.44M
29.00M
26.80M
24.89M
Total operating expenses
32.50M
33.54M
31.81M
30.32M
Operating income
-9.90M
-12.96M
-9.06M
-7.49M
Other non operating income
81.00K
277.00K
99.00K
-64.00K
EBT including unusual items
-10.24M
-13.50M
-9.95M
-8.24M
EBT excluding unusual items
-10.24M
-13.50M
-9.95M
-8.24M
Income tax expense
186.00K
149.00K
133.00K
151.00K
Effective tax rate
-1.82%
-1.10%
-1.34%
-1.83%
Other operating expenses
-
-
-
-
Net income
-10.42M
-13.65M
-10.08M
-8.39M
Net profit margin
-46.13%
-66.33%
-44.30%
-36.76%
Earnings per share
-0.25
-0.33
-0.24
-0.19
Interest and investment income
453.00K
350.00K
329.00K
345.00K
Interest expense
-770.00K
-976.00K
-1.22M
-1.23M
Net interest expenses
-317.00K
-626.00K
-889.00K
-889.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-9.57M
-12.84M
-8.84M
-7.18M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps